Meridian settles with Astra over peptic ulcer patent

By Elaine Rigoli

Tampa, Fla., April 12 - Meridian Bioscience, Inc. has reached a settlement agreement with Astra Srl regarding Meridian's patented technology for detecting H. pylori, the primary cause of peptic ulcers.

In the agreement, Astra acknowledges the existence, validity and scope of Meridian's patent, EPO 0806667, according to a news release.

Astra also will stop any promotion or distribution of the infringing products and, for any existing customers, will replace the Astra product with Meridian HpSA products, the release said.

Astra is a biotechnology company headquartered in Milan, Italy.

Cincinnati-based Meridian manufactures diagnostic test kits, purified reagents and related products, and offers biopharmaceutical-enabling technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.